生产企业：AstraZeneca
Baxdrostat (Baxfendy) is a novel, first-in-class aldosterone synthase inhibitor approved by the FDA for lowering blood pressure in patients with hypertension when used in combination with other antihypertensive agents.
Baxdrostat (Baxfendy) is a novel, first-in-class aldosterone synthase inhibitor approved by the FDA for lowering blood pressure in patients with hypertension when used in combination with other antihypertensive agents.
Baxdrostat is an aldosterone synthase inhibitor with higher potency than other enzymes targeting the same pathway. It inhibits the process the body uses to retain sodium and water, thereby reducing blood pressure through a mechanism distinct from existing antihypertensive classes.
共 2 项相关疾病
